Otsuka to use IPO money to fund buyouts; Covagen closes Series A;

 @FierceBiotech: The Best of FierceBiotech 2010. Report | Follow @FierceBiotech

> Japan's Otsuka is reportedly telling investors that it will use the money raised from its IPO to fund the acquisition of drug businesses. Story

> Switzerland's Covagen says it closed a Series A financing round in which CHF 6.3 million was raised. Covagen release

Special Report: FierceBiotech's Top Writers in Biotech. Report

> Quintiles and London Genetics are teaming up on a new personalized medicines initiative. Quintiles release

> Merck says it is halting studies of a single dose of the HIV drug Isentress after pondering data demonstrating its inferiority to a twice-daily dose. Story

Special Report: The Top 10 Phase III Failures of 2010. Report

> Medicago announced an extension to its partnering agreement of July 2009 with Genopole. Medicago release

And Finally... By tweaking a gene, scientists say they were able to reverse the age-related decline of mice. Story

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.